GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Additional Paid-In Capital

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Additional Paid-In Capital : $5.62 Mil(As of Jan. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Additional Paid-In Capital?


Cotinga Pharmaceuticals's quarterly additional paid-in capital declined from Jul. 2019 ($5.52 Mil) to Oct. 2019 ($5.50 Mil) but then increased from Oct. 2019 ($5.50 Mil) to Jan. 2020 ($5.62 Mil).

Cotinga Pharmaceuticals's annual additional paid-in capital declined from Apr. 2017 ($27.04 Mil) to Apr. 2018 ($5.11 Mil) but then increased from Apr. 2018 ($5.11 Mil) to Apr. 2019 ($5.41 Mil).

Cotinga Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Cotinga Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Additional Paid-In Capital Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.37 25.87 27.04 5.11 5.41

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.94 5.41 5.52 5.50 5.62

Cotinga Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Cotinga Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Additional Paid-In Capital
Comparable Companies
TSXV:MFS TSXV:PBS TSXV:APC TSXV:WAVE XCNQ:NSHS OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY HKSE:02269 OCSE:GMAB HKSE:01177 SZSE:300122 BMRN
Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Website
http://www.cotingapharma.com
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018